Margaret L Salisbury1, Meng Xia2, Yueren Zhou2, Susan Murray2, Nabihah Tayob3, Kevin K Brown4, Athol U Wells5, Shelley L Schmidt6, Fernando J Martinez7, Kevin R Flaherty8. 1. Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Michigan, Ann Arbor, MI. Electronic address: msalisbu@med.umich.edu. 2. Department of Biostatistics, University of Michigan, Ann Arbor, MI. 3. Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX. 4. Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, National Jewish Health, Denver, CO. 5. Interstitial Lung Disease Unit, Royal Brompton and Harefield National Health Service Foundation Trust, London, England. 6. Pulmonary Medicine, Spectrum Health, Grand Rapids, MI. 7. Pulmonary and Critical Care Medicine, Cornell Medical College, New York, NY. 8. Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Michigan, Ann Arbor, MI.
Abstract
BACKGROUND: Idiopathic pulmonary fibrosis is a progressive lung disease with variable course. The Gender-Age-Physiology (GAP) Index and staging system uses clinical variables to stage mortality risk. It is unknown whether clinical staging predicts future decline in pulmonary function. We assessed whether the GAP stage predicts future pulmonary function decline and whether interval pulmonary function change predicts mortality after accounting for stage. METHODS: Patients with idiopathic pulmonary fibrosis (N = 657) were identified retrospectively at three tertiary referral centers, and baseline GAP stages were assessed. Mixed models were used to describe average trajectories of FVC and diffusing capacity of the lung for carbon monoxide (Dlco). Multivariable Cox proportional hazards models were used to assess whether declines in pulmonary function ≥ 10% in 6 months predict mortality after accounting for GAP stage. RESULTS: Over a 2-year period, GAP stage was not associated with differences in yearly lung function decline. After accounting for stage, a 10% decrease in FVC or Dlco over 6 months independently predicted death or transplantation (FVC hazard ratio, 1.37; Dlco hazard ratio, 1.30; both, P ≤ .03). Patients with GAP stage 2 with declining pulmonary function experienced a survival profile similar to patients with GAP stage 3, with 1-year event-free survival of 59.3% (95% CI, 49.4-67.8) vs 56.9% (95% CI, 42.2-69.1). CONCLUSIONS: Baseline GAP stage predicted death or lung transplantation but not the rate of future pulmonary function decline. After accounting for GAP stage, a decline of ≥ 10% over 6 months independently predicted death or lung transplantation.
BACKGROUND:Idiopathic pulmonary fibrosis is a progressive lung disease with variable course. The Gender-Age-Physiology (GAP) Index and staging system uses clinical variables to stage mortality risk. It is unknown whether clinical staging predicts future decline in pulmonary function. We assessed whether the GAP stage predicts future pulmonary function decline and whether interval pulmonary function change predicts mortality after accounting for stage. METHODS:Patients with idiopathic pulmonary fibrosis (N = 657) were identified retrospectively at three tertiary referral centers, and baseline GAP stages were assessed. Mixed models were used to describe average trajectories of FVC and diffusing capacity of the lung for carbon monoxide (Dlco). Multivariable Cox proportional hazards models were used to assess whether declines in pulmonary function ≥ 10% in 6 months predict mortality after accounting for GAP stage. RESULTS: Over a 2-year period, GAP stage was not associated with differences in yearly lung function decline. After accounting for stage, a 10% decrease in FVC or Dlco over 6 months independently predicted death or transplantation (FVC hazard ratio, 1.37; Dlco hazard ratio, 1.30; both, P ≤ .03). Patients with GAP stage 2 with declining pulmonary function experienced a survival profile similar to patients with GAP stage 3, with 1-year event-free survival of 59.3% (95% CI, 49.4-67.8) vs 56.9% (95% CI, 42.2-69.1). CONCLUSIONS: Baseline GAP stage predicted death or lung transplantation but not the rate of future pulmonary function decline. After accounting for GAP stage, a decline of ≥ 10% over 6 months independently predicted death or lung transplantation.
Authors: Ganesh Raghu; Kevin K Brown; Ulrich Costabel; Vincent Cottin; Roland M du Bois; Joseph A Lasky; Michiel Thomeer; James P Utz; Rezaul K Khandker; Lawrence McDermott; Saeed Fatenejad Journal: Am J Respir Crit Care Med Date: 2008-07-31 Impact factor: 21.405
Authors: Roland M du Bois; Derek Weycker; Carlo Albera; Williamson Z Bradford; Ulrich Costabel; Alex Kartashov; Lisa Lancaster; Paul W Noble; Ganesh Raghu; Steven A Sahn; Javier Szwarcberg; Michiel Thomeer; Dominique Valeyre; Talmadge E King Journal: Am J Respir Crit Care Med Date: 2011-08-15 Impact factor: 21.405
Authors: Luca Richeldi; Christopher J Ryerson; Joyce S Lee; Paul J Wolters; Laura L Koth; Brett Ley; Brett M Elicker; Kirk D Jones; Talmadge E King; Jay H Ryu; Harold R Collard Journal: Thorax Date: 2012-03-17 Impact factor: 9.139
Authors: Kevin R Flaherty; Jeanette A Mumford; Susan Murray; Ella A Kazerooni; Barry H Gross; Thomas V Colby; William D Travis; Andrew Flint; Galen B Toews; Joseph P Lynch; Fernando J Martinez Journal: Am J Respir Crit Care Med Date: 2003-05-28 Impact factor: 21.405
Authors: Brett Ley; Christopher J Ryerson; Eric Vittinghoff; Jay H Ryu; Sara Tomassetti; Joyce S Lee; Venerino Poletti; Matteo Buccioli; Brett M Elicker; Kirk D Jones; Talmadge E King; Harold R Collard Journal: Ann Intern Med Date: 2012-05-15 Impact factor: 25.391
Authors: Panagiota I Latsi; Roland M du Bois; Andrew G Nicholson; Thomas V Colby; Danai Bisirtzoglou; Ageliki Nikolakopoulou; Srihari Veeraraghavan; David M Hansell; Athol U Wells Journal: Am J Respir Crit Care Med Date: 2003-06-05 Impact factor: 21.405
Authors: Talmadge E King; Williamson Z Bradford; Socorro Castro-Bernardini; Elizabeth A Fagan; Ian Glaspole; Marilyn K Glassberg; Eduard Gorina; Peter M Hopkins; David Kardatzke; Lisa Lancaster; David J Lederer; Steven D Nathan; Carlos A Pereira; Steven A Sahn; Robert Sussman; Jeffrey J Swigris; Paul W Noble Journal: N Engl J Med Date: 2014-05-18 Impact factor: 91.245
Authors: Soraya Hengsawas Surasarang; Galina Florova; Andrey A Komissarov; Sreerama Shetty; Steven Idell; Robert O Williams Journal: Drug Dev Ind Pharm Date: 2017-11-10 Impact factor: 3.225
Authors: Margaret L Salisbury; David A Lynch; Edwin J R van Beek; Ella A Kazerooni; Junfeng Guo; Meng Xia; Susan Murray; Kevin J Anstrom; Eric Yow; Fernando J Martinez; Eric A Hoffman; Kevin R Flaherty Journal: Am J Respir Crit Care Med Date: 2017-04-01 Impact factor: 21.405
Authors: Brett Ley; Williamson Z Bradford; Eric Vittinghoff; Derek Weycker; Roland M du Bois; Harold R Collard Journal: Am J Respir Crit Care Med Date: 2016-09-15 Impact factor: 21.405
Authors: Joseph Jacob; Brian J Bartholmai; Srinivasan Rajagopalan; Coline H M van Moorsel; Hendrik W van Es; Frouke T van Beek; Marjolijn H L Struik; Maria Kokosi; Ryoko Egashira; Anne Laure Brun; Arjun Nair; Simon L F Walsh; Gary Cross; Joseph Barnett; Angelo de Lauretis; Eoin P Judge; Sujal Desai; Ronald Karwoski; Sebastien Ourselin; Elisabetta Renzoni; Toby M Maher; Andre Altmann; Athol U Wells Journal: Am J Respir Crit Care Med Date: 2018-09-15 Impact factor: 30.528
Authors: Grace Hyun J Kim; Stephan S Weigt; John A Belperio; Matthew S Brown; Yu Shi; Joshua H Lai; Jonathan G Goldin Journal: Eur Radiol Date: 2019-08-26 Impact factor: 5.315